SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE
Status:
Withdrawn
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a single-label open-arm mechanistic clinical study recruiting patients with psoriasis
or psoriatic arthritis with elevated cardiovascular risk. Subjects enrolled in this study
will receive statin treatment with rosuvastatin. The statin treatment in this study will be
used as an intervention with widely known pleiotropic CV risk reduction effects, including
anti-inflammatory reduction. Subjects will be studied before statin therapy and followed for
48 weeks on treatment. The primary outcome will be change in the coronary flow reserve (CFR)
as measured by cardiac PET. Overall, this study will examine the impact of statin therapy on
changes in CFR as a reflection of impaired coronary vasoreactivity and a manifestation of
myocardial ischemia, which may precede clinical CV events (and visible changes in plaque
morphology) in high-risk patients with psoriatic disease.